Estrogen Blockers Market, By Product Type (Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Downregulators (ERDs), Others), By Application (Breast Cancer Treatment, Hormone Replacement Therapy (HRT), Infertility Trea

Estrogen Blockers Market, By Product Type (Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Downregulators (ERDs), Others), By Application (Breast Cancer Treatment, Hormone Replacement Therapy (HRT), Infertility Treatment, Post-Menopausal Osteoporosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Estrogen blockers are medicines that are used by FTM (female to male) individuals as part of their hormone replacement therapy (HRT) to suppress the effects of estrogen in the body. They can also help to promote the development of male secondary sexual characteristics. There are many different types of estrogen blockers available, and some are more effective than others.

Estrogen blockers can be taken in the form of tablets or injections. They are usually prescribed as part of a larger HRT treatment plan and are generally well tolerated by individuals who take them. For the most part, a hospital stay is not required when taking these medications, and they can often be given at home.

Market Dynamics

Estrogen blockers are largely used to treat hormone-related diseases like polycystic ovary syndrome (PCOS), endometriosis, and breast cancer. The demand for estrogen blockers rises as the prevalence of these illnesses rises internationally, fueling market expansion.

For instance, on June 28, 2023, according to a report published by the World Health Organization, reported that polycystic ovary syndrome (PCOS) is a significant public health problem and considered as one of the commonest hormonal disturbances affecting women of reproductive age. The condition affects an estimated 8–13% of women of reproductive age every year, and up to 70% of cases are undiagnosed.

On the other hand, like any drug, estrogen blockers have potential risks and adverse effects. Hot flashes, mood swings, joint discomfort, and increases in cholesterol levels are examples of typical side effects. In some circumstances, long-term use of estrogen blockers may raise the risk of cardiovascular issues and bone loss. Patients' compliance with and acceptance of estrogen blockers may be impacted by safety worries and possible side effects.

Key features of the study:

• This report provides in-depth analysis of the global estrogen blockers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global estrogen blockers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., Novartis AG, AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie Inc., GlaxoSmithKline plc, Olema Pharmaceuticals, Inc., Scorpion Therapeutics, Inc., Allorion Therapeutics Inc, Carrick Therapeutics Limited, Criterium, Inc. and Hoffmann-La Roche
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global estrogen blockers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global estrogen blockers market

Detailed Segmentation:

• Global Estrogen Blockers Market, By Product Type:
• Selective Estrogen Receptor Modulators (SERMs)
• Aromatase Inhibitors
• Estrogen Receptor Downregulators (ERDs)
• Others
• Global Estrogen Blockers Market, By Application:
• Breast Cancer Treatment
• Hormone Replacement Therapy (HRT)
• Infertility Treatment
• Post-Menopausal Osteoporosis
• Others
• Global Estrogen Blockers Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Estrogen Blockers Market, By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Global Estrogen Blockers Market, By Company:
• Pfizer Inc.
• Novartis AG
• AstraZeneca PLC
• Eli Lilly and Company
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Sanofi S.A.
• AbbVie Inc.
• GlaxoSmithKline plc
• Olema Pharmaceuticals, Inc.
• Scorpion Therapeutics, Inc.
• Allorion Therapeutics Inc
• Carrick Therapeutics Limited
• Criterium, Inc.
• F.Hoffmann-La Roche